Bioline RX

BioLineRx Ltd. is a clinical stage biopharmaceutical company, which focuses on oncology. Its pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is a immunotherapy treatment used fro multiple solid tumors. The company was founded in 2003 and is headquartered in Modi'in, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumors. The company was founded in 2003 and is headquartered in Modi'in, Israel.

BioLineRx Ltd. (NASDAQ:BLRX ) Q3 2024 Earnings Conference Call November 25, 2024 8:30 AM ET Company Participants John Lacey - Head of IR & Corporate Communications Phil Serlin - CEO Mali Zeevi - CFO Conference Call Participants Joe Pantginis - HC Wainwright Justin Walsh - Jones Trading John Vandermosten - Zacks Operator Ladies and gentlemen, thank you for standing by.

BioLineRx Ltd. (BLRX) Q3 2024 Earnings Call Transcript

- Executed license agreement with Ayrmid Ltd. for APHEXDA ® (motixafortide) for $10 million upfront, up to $87 million in commercial milestones, and 18-23% tiered royalties on sales - - Received $9 million equity investment from certain funds managed by Highbridge Capital Management, LLC - - Entered into agreement to reduce and restructure long-term debt by ~$16.5 million - - Annual operational expenses expected to decline by over 70% following out-license of APHEXDA ® (motixafortide) commercial program to Ayrmid - - Company to continue to support motixafortide PDAC program while evaluating additional assets for development in rare diseases and oncology - - Management to host conference call today, November 25, at 8:30 am EDT - TEL AVIV, Israel , Nov. 25, 2024 /PRNewswire/ -- BioLineRx Ltd.

BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value

– BioLineRx to receive $10 million upfront payment from Ayrmid Ltd. (parent company of Gamida Cell) plus up to $87 million in commercial milestones, as well as royalties on net sales ranging from 18% to 23% – – BioLineRx retains rights to develop and commercialize motixafortide in solid tumors, including PDAC –  – BioLineRx received $9 million equity investment from certain funds managed by Highbridge Capital Management, LLC to support company's pipeline and expansion – – Trans actions enable significant reduction in BioLineRx's operational expenses and debt, and allow the company to focus on development activities in areas of high unmet need in oncology and rare diseases – – BioLineRx will provide further corporate updates on its Q3 results conference call, which is scheduled for November 25 at 8:30 am ET – TEL AVIV, Israel , Nov. 21, 2024 /PRNewswire/ -- BioLineRx Ltd.

BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.

Management to Hold Conference Call at 8:30 a.m. EST TEL AVIV, Israel , Nov. 20, 2024 /PRNewswire/ -- BioLineRx Ltd.

BioLineRx to Report Third Quarter 2024 Results on November 25, 2024

- Findings suggest motixafortide alone, and in combination with natalizumab, could support the collection of the large number of stem cells required by gene therapies for sickle cell disease within a single apheresis cycle -  - Data from proof-of-concept study shows that motixafortide was safe and well tolerated - - Oral presentation at ASH 2024 on Saturday, December 7, 2024 in San Diego, California - TEL AVIV, Israel and WALTHAM, Mass. , Nov. 5, 2024 /PRNewswire/ -- BioLineRx Ltd.

BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024

– Allowance strengthens company's intellectual property estate and extends motixafortide patent protection in the U.S. through December 2041 – TEL AVIV, Israel , Oct. 16, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent, titled, "COMPOSITION OF BL-8040," which covers the composition of motixafortide (APHEXDA®/BL-8040).

BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide

Patient survey currently underway in partnership with the HealthTree Foundation; data expected in Q1 2025 TEL AVIV, Israel and WALTHAM, Mass. , Sept. 17, 2024 /PRNewswire/ -- BioLineRx Ltd.

BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection

BioLineRx Ltd. (NASDAQ:BLRX ) Q2 2024 Earnings Conference Call August 15, 2024 8:30 AM ET Company Participants John Lacey - Head of IR and Corporate Communications Phil Serlin - CEO Holly May - President of BioLineRx USA Mali Zeevi - CFO Ella Sorani - Chief Development Officer Conference Call Participants John Vandermosten - Zacks Operator Ladies and gentlemen, thank you for standing by.

BioLineRx Ltd. (BLRX) Q2 2024 Earnings Call Transcript

- Secured APHEXDA® formulary placement among top 80 transplant centers representing ~37% of stem cell transplant procedures performed, surpassing stated goal for quarter; on-track to reach goal of ~60% by end of Q4 - - Doubled the number of centers ordering APHEXDA during the second quarter - - Entered into clinical trial agreement with St. Jude Children's Research Hospital to evaluate motixafortide for hematopoietic stem cell mobilization for gene therapies in sickle cell disease - - Management to host conference call today, August 15, at 8:30 am EDT - TEL AVIV, Israel , Aug. 15, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the second quarter ended June 30, 2024, and provided recent corporate and portfolio updates.

BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates

Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel , Aug. 8, 2024 /PRNewswire/ -- BioLineRx Ltd.

BioLineRx to Report Second Quarter 2024 Results on August 15, 2024

Adial Pharmaceuticals Inc

Enviva Partners

Knightscope

aTyr Pharma

Reliance Global Group

Society Pass

Making millions through the stock market is only possible in a few ways. Investors need one of these three things: Massive sums of capital to begin with Decades of time and more modest sums of capital More modest sums of capital and a combination of risk and luck We will be talking about the latter today: seven stocks you can buy for $2 that can 10X by 2025.

Millionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025

- Investigator-initiated study includes leading researchers in SCD gene therapy clinical development from St. Jude Children's Research Hospital, Inc. and two other clinical sites -   - New trial to expand ongoing clinical research of motixafortide for mobilization of HSCs in patients with SCD - TEL AVIV, Israel , May 30, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced a multi-center Phase 1 clinical trial sponsored  by St. Jude Children's Research Hospital, Inc. to evaluate motixafortide for the mobilization of CD34+ hematopoietic stem cells (HSCs) used in the development of gene therapies for patients with sickle cell disease (SCD).

BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD)

BioLineRx Ltd. (NASDAQ:BLRX ) Q1 2024 Earnings Call Transcript May 28, 2024 8:30 AM ET Company Participants John Lacey - Head of IR and Corporate Communications Phil Serlin - CEO Holly May - President of BioLineRx USA Mali Zeevi - CFO Conference Call Participants Joe Pantginis - HC Wainwright John Vandermosten - Zacks Operator Ladies and gentlemen, thank you for standing by.

BioLineRx Ltd. (BLRX) Q1 2024 Earnings Call Transcript

- Steady growth in APHEXDA ®  adoption in first full quarter post-approval - - Among top 80 transplant centers, secured APHEXDA formulary placement to date at institutions representing ~26% of stem cell transplant procedures performed - on track to reach stated goal of ~35% by end of Q2 - - Announced new data in abstract accepted at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting on pilot phase of ongoing Phase 2b pancreatic cancer clinical trial collaboration with Columbia University  - - Collaboration partner Gloria Biosciences' motixafortide HSC mobilization bridging study IND was filed and approved by the Center for Drug Evaluation of the National Medical Products Administration in China. Anticipate clinical trial initiation 2H 2024 - - Completed debt and equity financing totaling $26 million to support U.S. commercialization of APHEXDA and advance lifecycle expansion activities  - - Management to host conference call today, May 28, at 8:30 am EDT - TEL AVIV, Israel , May 28, 2024 /PRNewswire/ -- BioLineRx Ltd.

BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates

New analysis of biopsy samples demonstrated a significant increase in CD8+ T-cell density in tumors from all 11 patients treated   7 of 11 patients in the pilot phase experienced a partial response, with 6 confirmed; 10 of 11 patients experienced disease control   Poster Presentation on Saturday, June 1, 2024 in Chicago, Illinois  TEL AVIV, Israel , May 24, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that an abstract including new data from the single-arm pilot phase of the investigator-initiated, randomized CheMo4METPANC Phase 2 combination clinical trial was accepted for presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31-June 4, 2024 in Chicago, Illinois.

BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting

Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel , May 22, 2024 /PRNewswire/ -- BioLineRx Ltd.

BioLineRx to Report First Quarter 2024 Results on May 28, 2024

TEL AVIV, Israel , May 17, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has received a notification letter from the Nasdaq Stock Market LLC ("Nasdaq").

BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification

- Presentation Today, Monday, May 6, 2024 in Atlanta, Georgia  - TEL AVIV, Israel , May 6, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that new economic model data will be presented on APHEXDA® (motixafortide) for CD34+ hematopoietic stem cell (HSC) mobilization in patients with multiple myeloma at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) – The Professional Society for Health Economics and Outcomes Research – 2024 conference, taking place May 5-8, 2024, in Atlanta, Georgia.

BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024

TEL AVIV, Israel , April 17, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced a poster presentation on apheresis center efficiency and CXCR4 antagonists including APHEXDA (motixafortide) in patients with multiple myeloma.

BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting

-  Proceeds to be used to further accelerate uptake of APHEXDA® in stem cell mobilization, life-cycle expansion activities in sickle cell disease, and motixafortide metastatic pancreatic cancer program - TEL AVIV, Israel , April 10, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has drawn-down the second tranche of $20 million under its previously announced $40 million non-dilutive debt financing agreement with funds and accounts managed by BlackRock.

BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement

TEL AVIV, Israel , April 1, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has entered into definitive agreements with several institutional investors for the issuance and sale in a registered direct offering of 7,500,000 of the Company's American Depositary Shares (ADSs) and warrants to purchase up to an aggregate of 7,500,000 ADSs, at a combined purchase price of $0.80 per ADS and accompanying warrant.

BioLineRx Announces $6 Million Registered Direct Offering

BioLineRx Ltd. (BLRX) Q4 2023 Earnings Call Transcript

- Reported significant commercial progress for APHEXDA® -- secured payer coverage representing ~95% of covered lives in the U.S.; continued progress on formulary approvals at targeted major transplant centers; r eceived Healthcare Common Procedure Coding System (HCPCS) J-Code to facilitate Medicare reimbursement - - Announced first patient dosed  in randomized Phase 2b clinical trial evaluating motixafortide in first-line pancreatic cancer - - Continued to support partner Gloria Biosciences in plans to execute pivotal bridging study of motixafortide in stem cell mobilization and Phase 2b randomized study in first-line pancreatic cancer in China - - Management to host conference call today, March 26, at 8:30 am EDT - TEL AVIV, Israel , March 26, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its financial results for the year ended December 31, 2023, and provided recent corporate and portfolio updates.

BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates

- Management to Hold Conference Call at 08:30 a.m. EDT - TEL AVIV, Israel , March 20, 2024 /PRNewswire/ -- BioLineRx Ltd.

BioLineRx to Report 2023 Annual Financial Results on March 26, 2024

Candel Therapeutics

Immuneering Corp

Oncolytics Biotech, Inc.

Vancouver, Kelowna and Delta, British Columbia--(Newsfile Corp. - March 6, 2024) - Investorideas.com, a global investor news source covering biotech and pharma stocks issues a sector snapshot on developments for pancreatic cancer treatments, featuring Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology. Read the full article on Investoorideas.com Research Nester says, "The global pancreatic cancer market size is slated to expand at ~18% CAGR between 2024 and 2036.

News for Bioline RX Stock (BLRX)